Abstract
In non-pregnant populations, LMWH dosage regimens provide effective therapy without the need to monitor factor Xa levels. It cannot be assumed that the pharmacokinetics of LMWH leads to a predictable factor Xa effect in pregnancy. Our objective was to assess the frequency of sub-prophylactic factor Xa levels across gestation in thrombophilic patients treated with dose adjusted LMWH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
